The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .
Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy.
OBJECTIVE To evaluate the effects of giving testosterone undecanoate ( TU ) in addition to estrogen replacement on serum lipids in oophorectomized women . METHOD Women with surgically induced menopause ( n = 50 ) were r and omly assigned to oral treatment with 2 mg of estradiol valerate in combination with 40 mg of TU or placebo for 24 weeks . The study was double-blind with cross-over to the other regimen for further 24 weeks of treatment . Forty-four women completed the study . Their serum concentrations of total , high density lipoprotein (HDL)- and low density lipoprotein (LDL)-cholesterol , triglycerides , lipoprotein-(a ) ( Lp-(a ) ) , total testosterone , estradiol and sex hormone-binding globulin ( SHBG )  were analyzed at baseline and after 24 weeks of each treatment . RESULTS Serum levels of total testosterone increased markedly from a baseline mean of 0.8 - 4.9 nmol/l during testosterone addition . The levels of free testosterone significantly increased during the combined treatment and fell when given estrogen alone . Total and LDL-cholesterol levels were significantly reduced by both treatments as also were those of Lp-(a ) although the difference was not significant . We found a 13 % reduction in HDL-cholesterol levels when testosterone was added , but no change with estrogen alone . Triglyceride levels were increased by estrogen treatment , but not affected by the combination of estrogen plus testosterone . CONCLUSIONS These findings suggest that 40 mg of TU can be given in addition to estrogen replacement with only little side-effects on the pattern of circulating lipids . Although supraphysiological concentrations of testosterone were induced a significant reduction in total and LDL-cholesterol levels occurred
The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .